Physician profile
Vienne Murray
NPI 1952385627
$2,404.68
in general payments reported to CMS, 2019-2025
33 companies · $430 in 2025
The $430 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $46.57 · 2021: $390 · 2022: $548 · 2023: $483 · 2024: $367 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $770.60 | 2019-2025 | |
| Coopersurgical, INC. | $192.73 | 2020-2024 | Paragard T 380a |
| Astellas Pharma US INC | $169.26 | 2023-2025 | Veozah, Myrbetriq |
| Organon LLC | $134.30 | 2021-2025 | Nexplanon |
| Pfizer INC. | $129.82 | 2019-2024 | |
| Biogen, INC. | $106.53 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $87.32 | 2022-2025 | |
| Hologic Sales and Service, LLC | $78.31 | 2021-2024 | Acessa Provu System, Myosure Tissue Removal Device |
| Exeltis, USA INC. | $65.28 | 2022-2024 | Slynd |
| Mayne Pharma Commercial LLC | $64.80 | 2023 | |
| Amgen INC. | $60.58 | 2024-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $52.22 | 2019-2023 | Gardasil 9 |
| Daiichi Sankyo INC. | $51.05 | 2024-2025 | Injectafer |
| Aspira Women'S Health INC | $48.02 | 2022-2023 | Ova1 |
| Minerva Surgical, INC | $45.56 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $34.26 | 2019 | |
| Millicent US INC | $30.67 | 2025 | Femlyv, Intrarosa |
| Renovia INC | $28.52 | 2021 | |
| Davol INC. | $24.93 | 2023 | Arista Ah Flexitip |
| Allergan, INC. | $23.62 | 2019 | |
| Medicem INC. | $22.31 | 2021 | |
| Mylan Pharmaceuticals INC. | $18.65 | 2021 | |
| Novo Nordisk INC | $17.90 | 2023 | |
| Sumitomo Pharma America, INC. | $16.79 | 2023 | Myfembree |
| Avion Pharmaceuticals | $16.18 | 2021 | |
| Ethicon US, LLC | $16.12 | 2021 | |
| Scynexis, INC. | $15.94 | 2022 | |
| Therapeuticsmd, INC. | $15.64 | 2020 | |
| Myovant Sciences INC. | $14.91 | 2022 | |
| Agile Therapeutics, INC. | $13.81 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $13.08 | 2022 | |
| Shield Therapeutics INC | $12.49 | 2022 | |
| Covidien LP | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vienne Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.